
| Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis #MMPMID32585161Fraga M; Moradpour D; Artru F; Romailler E; Tschopp J; Schneider A; Chtioui H; Neerman-Arbez M; Casini A; Alberio L; Sempoux CJ Hepatol 2020[Oct]; 73 (4): 967-970 PMID32585161show ga
?|*Coronavirus Infections/diagnosis/physiopathology[MESH]|*Hepatitis/etiology/pathology/physiopathology[MESH]|*Liver/diagnostic imaging/pathology[MESH]|*Pandemics[MESH]|*Pneumonia, Viral/diagnosis/physiopathology[MESH]|Betacoronavirus/*isolation & purification[MESH]|COVID-19[MESH]|Diagnosis, Differential[MESH]|Fibrinogen/*analysis[MESH]|Glycogen Storage Disease Type IV/diagnosis[MESH]|Hepatitis B, Chronic/diagnosis[MESH]|Humans[MESH]|Inclusion Bodies/*pathology[MESH]|Lafora Disease/diagnosis[MESH]|Liver Function Tests/methods[MESH]|Male[MESH]|Middle Aged[MESH]|Patient Care Management/methods[MESH]|Pneumonia, Ventilator-Associated/therapy[MESH]|Pulmonary Embolism/diagnosis/etiology/physiopathology[MESH]|Respiration, Artificial/adverse effects/methods[MESH]|SARS-CoV-2[MESH]
  
DeepDyve Pubget Overpricing | 
|